Intravitreal bevacizumab (Avastin) injection in retinitis pigmentosa


Yuzbasioglu E., ARTUNAY H. Ö., Rasier R., Sengul A., Bahcecioglu H.

Current Eye Research, cilt.34, sa.3, ss.231-237, 2009 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 34 Sayı: 3
  • Basım Tarihi: 2009
  • Doi Numarası: 10.1080/02713680802710692
  • Dergi Adı: Current Eye Research
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.231-237
  • Anahtar Kelimeler: Avastin, intravitreal bevacizumab, macular edema, retinal dystrophies, retinitis pigmentosa
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Purpose: To evaluate and report the effectiveness, visual, anatomical, and clinical outcome of intravitreal bevacizumab (Avastin) injection in patients with retinitis pigmentosa (RP). Methods: Our prospective study included 13 eyes of 7 patients (4 women and 3 men) in the age range of 25-69 years (mean 44.14 years) with cystoid macular edema (CME) secondary to RP. Intravitreal bevacizumab at a dose of 1.25 mg/0.05 ml was injected via a 28-gauge needle. The response rate to treatment was monitored functionally by visual acuity assessment and anatomically using the optical coherence tomography. Results: The baseline mean central macular thickness was 370.15 μm (range 245-603 μm. The central macular thickness decreased to 142.53 μm (range 124-168 μm) after bevacizumab injections. The pre- and post-treatment visual acuity ranges were 5/400-20/100 and 20/200-20/63, respectively. Conclusions: Our data reveal that intravitreal bevacizumab administration is effective for the treatment of CME in RP. Further studies with a larger population and longer follow-up period are warranted to assess the efficacy of the treatment. Copyright © Informa Healthcare USA, Inc.